Jameel Fund launches second round supporting projects tackling deadly coronaviruses and other respiratory viruses at Imperial College London and King Abdulaziz University
The Jameel Fund for Infectious Disease Research and Innovation has launched its second round of funding for research and innovation tackling the transmission and pathogenesis of deadly coronaviruses, including COVID-19, SARS and MERS, and other respiratory viruses. The fund supports researchers at Imperial College London and King Abdulaziz University (KAU) in Jeddah, Saudi Arabia, and promotes cross-institutional research in the field of infectious diseases.
The call is open to academic and honorary clinical staff at Imperial and KAU. Research proposals are evaluated by a joint committee comprising representatives from Imperial, KAU and experts in the field. Successful applicants will begin their projects at their respective institutions by October 1, 2022.
Established in 2021 by Community Jameel and Community Jameel Saudi Arabia, the Jameel Fund provides awards of up to USD 65,000 for short-term, high-impact projects at Imperial College London and King Abdulaziz University (KAU) in Jeddah that advance our ability to understand, prevent, diagnose, and treat coronaviruses and other infectious diseases. The fund was also set up with a view to strengthening research collaborations between Imperial and Saudi universities in this field that advance our ability to understand, prevent, diagnose, and treat coronaviruses and other infectious diseases. KAU is the highest ranked university in the Arab region, according to the World University Rankings 2021, with strengths in infectious disease research. The fund was also set up with a view to strengthening research collaborations between Imperial and Saudi universities in this field. KAU is the highest ranked university in the Arab region, according to the 2022 QS World University Rankings.
The first round of the Jameel Fund, in 2021, also focused on coronaviruses and supported projects ranging from understanding genetic basis of severe SARS-CoV-2 associated disease inchildren, to a platform for the rapid design-through-manufacture of respiratory protective equipment.
